» Articles » PMID: 30894686

Exome and Immune Cell Score Analyses Reveal Great Variation Within Synchronous Primary Colorectal Cancers

Abstract

Background: Approximately 4% of colorectal cancer (CRC) patients have at least two simultaneous cancers in the colon. Due to the shared environment, these synchronous CRCs (SCRCs) provide a unique setting to study colorectal carcinogenesis. Understanding whether these tumours are genetically similar or distinct is essential when designing therapeutic approaches.

Methods: We performed exome sequencing of 47 primary cancers and corresponding normal samples from 23 patients. Additionally, we carried out a comprehensive mutational signature analysis to assess whether tumours had undergone similar mutational processes and the first immune cell score analysis (IS) of SCRC to analyse the interplay between immune cell invasion and mutation profile in both lesions of an individual.

Results: The tumour pairs shared only few mutations, favouring different mutations in known CRC genes and signalling pathways and displayed variation in their signature content. Two tumour pairs had discordant mismatch repair statuses. In majority of the pairs, IS varied between primaries. Differences were not explained by any clinicopathological variable or mutation burden.

Conclusions: The study shows major diversity within SCRCs. Rather than rely on data from one tumour, our study highlights the need to evaluate both tumours of a synchronous pair for optimised targeted therapy.

Citing Articles

A clinico-pathological and molecular analysis reveals differences between solitary (early and late-onset) and synchronous rectal cancer.

Perea J, Garcia J, Corchete L, Tapial S, Olmedillas-Lopez S, Vivas A Sci Rep. 2021; 11(1):2202.

PMID: 33500439 PMC: 7838158. DOI: 10.1038/s41598-020-79118-z.


Personalised mapping of tumour development in synchronous colorectal cancer patients.

Thomas V, Cotter M, Tosetto M, Khaw Y, Geraghty R, Winter D NPJ Genom Med. 2020; 5:27.

PMID: 32655884 PMC: 7335056. DOI: 10.1038/s41525-020-0134-3.


53BP1 expression and immunoscore are associated with the efficacy of neoadjuvant chemoradiotherapy for rectal cancer.

Huang A, Xiao Y, Peng C, Liu T, Lin Z, Yang Q Strahlenther Onkol. 2019; 196(5):465-473.

PMID: 31828392 DOI: 10.1007/s00066-019-01559-x.

References
1.
Di J, Yang H, Jiang B, Wang Z, Ji J, Su X . Whole exome sequencing reveals intertumor heterogeneity and distinct genetic origins of sporadic synchronous colorectal cancer. Int J Cancer. 2017; 142(5):927-939. DOI: 10.1002/ijc.31140. View

2.
Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen J . Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res. 2007; 35(Web Server issue):W71-4. PMC: 1933133. DOI: 10.1093/nar/gkm306. View

3.
Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M . Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000; 18(11):2193-200. DOI: 10.1200/JCO.2000.18.11.2193. View

4.
Alexandrov L, Nik-Zainal S, Wedge D, Campbell P, Stratton M . Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013; 3(1):246-59. PMC: 3588146. DOI: 10.1016/j.celrep.2012.12.008. View

5.
Lievre A, Bachet J, Le Corre D, Boige V, Landi B, Emile J . KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66(8):3992-5. DOI: 10.1158/0008-5472.CAN-06-0191. View